@@ Despite recent advances in antibiotic therapy and intensive care, sepsis is still considered to be the most common cause of death in intensive care units (ICU), which is a complex, incompletely understood and often fatal disorder, typically accompanied by multiple organ dysfunction (1, 2). Over 750, 000 people become septic each year with a mortality rate of 30-40％ and an approximate cost of $16.7 billion in the United States alone (1, 2). Because the factors responsible for the pathology and death associated with sepsis are not fully understood (3), it has been exceedingly difficult to develop measures that reduce so high mortality. Thus, there is considerable interest in identifying an effective novel therapy for this disorder.